Alexander Muik

BioNTech (Germany) — Germany

Medicine · Health Sciences

33h-index8.5kcitations111works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(49), Animal Virus Infections Studies(30), Virus-based gene therapy research(27), Immunotherapy and Immune Responses(23), CAR-T cell therapy research(22)

Publications111 total

Figure 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 3 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Table 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
2025Open Access
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines
Nature Communications·2025· 1 citedOpen Access
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade
Scientific Reports·2025Open Access
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Nature·2025· 1 citedOpen Access
Dose Selection for <scp>DuoBody</scp>®‐<scp>CD40x4</scp>‐<scp>1BB</scp> (<scp>GEN1042</scp>/<scp>BNT312</scp>) Using a <scp>mPBPK</scp>/<scp>RO</scp> Model Leveraging Preclinical and Clinical Data
Clinical Pharmacology & Therapeutics·2025· 2 citedOpen Access
Abstract 6075: The combination of an EpCAMx4-1BB bispecific antibody with PD-1 blockade exhibits antitumor activity in a murine tumor model unresponsive to each individual antibody
Cancer Research·2025
Abstract 6061: Dual PD-L1 blockade and VEGF-A neutralization with the bispecific antibody BNT327/PM8002 shows potent antitumor activity in preclinical models
Cancer Research·2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects
Journal for ImmunoTherapy of Cancer·2025· 8 citedOpen Access
Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection
2025
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
npj Vaccines·2024· 11 citedOpen Access
731 The combination of an EpCAMx4–1BB bispecific antibody with PD-1 blockade potentiates single-agent effects on T-cell functions and enhances antitumor activity in preclinical studies
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
UNC Libraries·2024Open Access
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine
Vaccine·2024· 1 citedOpen Access
Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1
Cell Reports·2024· 5 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Uğur Şahin(32), Özlem Türeci(25), Kena A. Swanson(21), Pei‐Yong Shi(17), Mark Cutler(14), David Cooper(14), Hui Cai(14), Philip R. Dormitzer(13), Bonny Gaby Lui(13), Kathrin U. Jansen(12), Camila R. Fontes-Garfias(10), Ann-Kathrin Wallisch(10), Bianca Sänger(9), Xuping Xie(9), Orkun Ozhelvaci(9), Qi Yang(9), Lena M. Kranz(8), Mathias Vormehr(8), Corinna Rosenbaum(8), Asaf Poran(8)